Caliper sheds jobs after Zymark buy

Related tags Time

Caliper has cut 9 per cent of its staff as part of a restructuring
exercise following its $72 million acquisition of lab automation
company Zymark.

Caliper Technologies has said that it will reduce its work force by approximately 50 positions, or 9 per cent of its total head count, as part of a restructuring exercise following its $71 million (€63.2m)acquisition of lab automation company Zymark.

Upon acquiring Zymark, Caliper moved its headquarters from Mountain View in California to Zymark's headquarters in Hopkinton, Massachusetts. Employees at both sites are affected by yesterday's announcement.

Caliper stressed that its research and development (R&D) organisation will remain unchanged at present "pending strategy and product priority decisions that will be made in the second half of 2003."

"This action sets the stage for Caliper to attain its goal of being profitable by the fourth quarter of 2005,"​ said Kevin Hrusovsky, the company's president and chief executive. He added that the consolidation will be a big step towards achieving the previously-announced minimum savings of $10 million annually by year end.

Related news

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us

Webinars

Headlines